Cargando…
Old unsolved problems: when and how to treat silent ischaemia
Silent myocardial ischaemia (SMI) is defined as objective evidence of ischaemia without angina (or equivalent symptoms) in the presence of coronary artery disease, differing from silent coronary artery disease. Silent myocardial ischaemia represents the majority of episodes of myocardial ischaemia a...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7904061/ https://www.ncbi.nlm.nih.gov/pubmed/33654471 http://dx.doi.org/10.1093/eurheartj/suaa141 |
_version_ | 1783654855696449536 |
---|---|
author | Indolfi, Ciro Polimeni, Alberto Mongiardo, Annalisa De Rosa, Salvatore Spaccarotella, Carmen |
author_facet | Indolfi, Ciro Polimeni, Alberto Mongiardo, Annalisa De Rosa, Salvatore Spaccarotella, Carmen |
author_sort | Indolfi, Ciro |
collection | PubMed |
description | Silent myocardial ischaemia (SMI) is defined as objective evidence of ischaemia without angina (or equivalent symptoms) in the presence of coronary artery disease, differing from silent coronary artery disease. Silent myocardial ischaemia represents the majority of episodes of myocardial ischaemia at Holter monitoring. During transient myocardial ischaemia, the symptoms appear after the contraction anomalies of the left ventricle and after the ECG changes. The cause of silent myocardial ischaemia is still not well established. The severity and duration of ischaemia have been theorized as important elements in the SMI mechanism. Another possible mechanism responsible for SMI is represented by changes in the perception of painful stimuli with an increased pain threshold. Finally, a neuronal dysfunction of the diabetic, in post-infarction or a cardiac neuronal ‘stunning’ could play a role in SMI. In the pre-stent era, the SMI was associated with a worse prognosis. In patients with diabetes mellitus, SMI seems to be more represented because autonomic dysfunction is present in this category of patients. In conclusion, SMI is more frequent than symptomatic ischaemia. However, despite the presence of countless studies on the subject, it is not clear today whether medical therapy has equalized the risk and what the real prognosis of SMI is. |
format | Online Article Text |
id | pubmed-7904061 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-79040612021-03-01 Old unsolved problems: when and how to treat silent ischaemia Indolfi, Ciro Polimeni, Alberto Mongiardo, Annalisa De Rosa, Salvatore Spaccarotella, Carmen Eur Heart J Suppl Articles Silent myocardial ischaemia (SMI) is defined as objective evidence of ischaemia without angina (or equivalent symptoms) in the presence of coronary artery disease, differing from silent coronary artery disease. Silent myocardial ischaemia represents the majority of episodes of myocardial ischaemia at Holter monitoring. During transient myocardial ischaemia, the symptoms appear after the contraction anomalies of the left ventricle and after the ECG changes. The cause of silent myocardial ischaemia is still not well established. The severity and duration of ischaemia have been theorized as important elements in the SMI mechanism. Another possible mechanism responsible for SMI is represented by changes in the perception of painful stimuli with an increased pain threshold. Finally, a neuronal dysfunction of the diabetic, in post-infarction or a cardiac neuronal ‘stunning’ could play a role in SMI. In the pre-stent era, the SMI was associated with a worse prognosis. In patients with diabetes mellitus, SMI seems to be more represented because autonomic dysfunction is present in this category of patients. In conclusion, SMI is more frequent than symptomatic ischaemia. However, despite the presence of countless studies on the subject, it is not clear today whether medical therapy has equalized the risk and what the real prognosis of SMI is. Oxford University Press 2020-11-18 /pmc/articles/PMC7904061/ /pubmed/33654471 http://dx.doi.org/10.1093/eurheartj/suaa141 Text en Published on behalf of the European Society of Cardiology. © The Author(s) 2020. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Articles Indolfi, Ciro Polimeni, Alberto Mongiardo, Annalisa De Rosa, Salvatore Spaccarotella, Carmen Old unsolved problems: when and how to treat silent ischaemia |
title | Old unsolved problems: when and how to treat silent ischaemia |
title_full | Old unsolved problems: when and how to treat silent ischaemia |
title_fullStr | Old unsolved problems: when and how to treat silent ischaemia |
title_full_unstemmed | Old unsolved problems: when and how to treat silent ischaemia |
title_short | Old unsolved problems: when and how to treat silent ischaemia |
title_sort | old unsolved problems: when and how to treat silent ischaemia |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7904061/ https://www.ncbi.nlm.nih.gov/pubmed/33654471 http://dx.doi.org/10.1093/eurheartj/suaa141 |
work_keys_str_mv | AT indolficiro oldunsolvedproblemswhenandhowtotreatsilentischaemia AT polimenialberto oldunsolvedproblemswhenandhowtotreatsilentischaemia AT mongiardoannalisa oldunsolvedproblemswhenandhowtotreatsilentischaemia AT derosasalvatore oldunsolvedproblemswhenandhowtotreatsilentischaemia AT spaccarotellacarmen oldunsolvedproblemswhenandhowtotreatsilentischaemia |